Gutiérrez CPL, López APJ, Moreno OV, Nuño DMF, Sánchez EAE

Language: Spanish
References: 26
Page:
PDF size: 251.98 Kb.

ABSTRACT

Cardiac fibrosis is a chronic condition characterized by the abnormal deposition of the extracellular matrix, leading to myocardial stiffness and impaired heart function. Currently, there are no specific therapies capable of reversing this pathology. Cellular immunotherapies, such as CAR-T and CAR-M cells, have transformed cancer treatment and are now being explored for non-oncological diseases. In animal models, CAR-T cells targeting activated fibroblasts have shown promising results by reducing fibrosis progression and improving cardiac function. In Mexico, academic institutions have successfully developed CAR-T cells for hematologic cancers, highlighting the potential to adapt this technology for chronic diseases like cardiac fibrosis. This article reviews the mechanisms of CAR- based therapies, their current applications and the feasibility of their implementation in the Mexican healthcare context.

REFERENCES

1. Instituto Nacional de Estadística y Geografía (INEGI). Sala de prensa [Internet]. 2025 [citado 7 abr 2025]. Disponible en: https://www.inegi.org.mx/app/saladeprensa/noticia/8771

2. Li R, Gan S, Zhang L, Broudy T, Hu Y. Abstract 2314: Pharmacology studies of chimeric antigen receptor (CAR) Tcells in luminescent xenograft and 3D in vitro tumor models. Cancer Res.2019 Jul 1;79(13 Suppl):2314.

3. Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ. In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes. Mol Ther. 2020 Aug5;28(8):1783-94.

4. McGraw Hill Medical. Terapia de células inmunitarias: células T genéticamente modificadas [Internet]. [citado 4 abr 2025]. Disponible en: https://accessmedicina.mhmedical.com/content.aspx?sectionid=279177424&bookid=3349

5. Sociedad Argentina de Hematología. Hematologia: Volumen 18 - Número Extraordinario. Buenos Aires: SAH; 2014. 65 p.

6. Golubovskaya V, Sienkiewicz J, Sun J, Zhang S, Huang Y, Zhou H, et al. CARNKCells Generated with mRNA-LNPsKill Tumor Target Cells In Vitro and InVivo. Int J Mol Sci. 2023 Aug29;24(17):13364.

7. Zhang Q, Dai J, Liu T, Rao W, Li D, GuZ, et al. Targeting cardiac fibrosis withChimeric Antigen Receptor-Engineered Cells. Mol Cell Biochem. 2025 Apr 1;480(4):2103-16.

8. National Institute of Allergy andInfectious Diseases (NIAID). BioArt [Internet]. [citado 7 abr 2025]. Disponible en: https://bioart.niaid.nih.gov/

9. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med. 2011 Aug25;365(8):725-33.

10. Zhang Y, Li S, Wang Y, Lu Y, Xu Y, Wang M, et al. Bispecific CAR-T cells targeting both CD19 and CD22 fortherapy of adults with relapsed orrefractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020 Mar12;13(1):30.

11. Feng J, Hu Y, Chang AH, Huang H. CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety andPreliminary Efficacy Data from a PhaseI Clinical Study. Blood. 2023 Nov 2;142(Suppl 1):4835.

12. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008 Jan;214(2):199-210.

13. Zhao M, Wang L, Wang M, Zhou S, LuY, Cui H, et al. Targeting fibrosis: mechanisms and clinical trials. Signal Transduct Target Ther. 2022 Jun30;7(1):206.

14. Vagnozzi RJ, Johansen AKZ, MolkentinJD. CARdiac Immunotherapy: T Cells Engineered to Treat the Fibrotic Heart. Mol Ther. 2019 Nov 6;27(11):1869-71.

15. Ye W, Lv X, Gao S, Li Y, Luan J, WangS. Emerging role of m6A modification in fibrotic diseases and its potentialtherapeutic effect. Biochem Pharmacol. 2023 Dec 1;218:115873.

16. Hinderer S, Schenke-Layland K. Cardiac fibrosis – A short review of causes and therapeutic strategies. Adv Drug Deliv Rev. 2019 Jun1;146:77-82.

17. Mesquita T, Lin Y, Ibrahim A. Chronic low‐grade inflammation in heartfailure with preserved ejection fraction. Aging Cell. 2021 Sep;20(9):e13453.

18. Conroy KP, Kitto LJ, Henderson NC. αv integrins: key regulators of tissue fibrosis. Cell Tissue Res. 2016 Sep;365(3):511-9.

19. Reed NI, Jo H, Chen C, Tsujino K, Arnold TD, DeGrado WF, et al. The αvβ1 integrin plays a critical in vivorole in tissue fibrosis. Sci Transl Med.

20. 2015 May 20;7(288):288ra79.20. Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2020 Nov 2;117(6):1450-88.

21. Mouton AJ, Li X, Hall ME, Hall JE. Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. Circ Res. 2020 Mar 13;126(6):789-806.

22. Zhang Q, Dai J, Liu T, Rao W, Li D, GuZ, et al. Targeting cardiac fibrosis withChimeric Antigen Receptor-Engineered Cells. Mol Cell Biochem. 2025 Apr 1;480(4):2103-16.

23. Majzner RG, Mackall CL. Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018 Oct 2;8(10):1219-26.

24. Gao Z, Yan L, Meng J, Lu Z, Ge K, Jiang Z, et al. Targeting cardiac fibrosis with chimeric antigen receptormacrophages. Cell Discov. 2024 Aug 13;10:86.

25. Liu M, López de Juan Abad B, ChengK. Cardiac fibrosis: Myofibroblastmediated pathological regulation and drug delivery strategies. Adv DrugDeliv Rev. 2021 Jun 1;173:504-19.

26. Rietdorf K, Bootman MD, Davidson SM. Treatment of Cardiac Fibrosis with Extracellular Vesicles: What Is Missingfor Clinical Translation? Int J Mol Sci. 2023 Jun 21;24(13):10480.